[BPMC] Blueprint Medicines Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 28.15 Change: 1.24 (4.61%)
Ext. hours: Change: 0 (0%)

chart BPMC

Refresh chart

Strongest Trends Summary For BPMC

BPMC is in the medium-term up 25% in 5 months and up 53% in 1 year. In the long-term up 194% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-550 K Cash From Investing Activities-1.28 M Cash From Operating Activities4.89 M Gross Profit
Net Profit-11.57 M Operating Profit-11.35 M Total Assets55.91 M Total Current Assets52.18 M
Total Current Liabilities14.63 M Total Debt8.65 M Total Liabilities31.19 M Total Revenue650 K
Technical Data
High 52 week101.41 Low 52 week45.57 Last close91.97 Last change-1.11%
RSI37.75 Average true range4.2 Beta1.51 Volume291.22 K
Simple moving average 20 days-4.05% Simple moving average 50 days-1.19% Simple moving average 200 days21.02%
Performance Data
Performance Week1.19% Performance Month-2.25% Performance Quart9.93% Performance Half25.75%
Performance Year31.72% Performance Year-to-date70.6% Volatility daily2.49% Volatility weekly5.57%
Volatility monthly11.41% Volatility yearly39.52% Relative Volume181.66% Average Volume487.74 K
New High New Low

News

2019-09-10 14:16:54 | Does Blueprint Medicines Corporation NASDAQ:BPMC Have A Particularly Volatile Share Price?

2019-09-09 16:39:08 | Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study

2019-09-05 21:16:00 | 4 Biotech Stocks With Big Catalysts in September

2019-08-31 09:32:01 | Why Is Blueprint Medicines BPMC Down 18.3% Since Last Earnings Report?

2019-08-28 08:00:00 | Blueprint Medicines to Present at Upcoming Investor Conferences in September

2019-08-21 19:15:20 | Blueprint Medicines Corp BPMC CEO and President Jeffrey W. Albers Sold $1.6 million of Shares

2019-08-14 16:28:16 | This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival

2019-08-13 10:19:48 | Deciphera stock surges on gastrointestinal cancer drug success

2019-08-07 08:00:00 | Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

2019-08-06 15:45:27 | The Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund

2019-08-06 08:50:50 | Edited Transcript of BPMC earnings conference call or presentation 1-Aug-19 12:30pm GMT

2019-08-06 08:00:00 | Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference

2019-08-04 15:04:00 | 3 Lung Cancer Stocks That Could Soar in September

2019-08-02 11:54:03 | Blueprint Medicines BPMC Q2 Loss Widens, Sales Top Mark

2019-08-02 00:24:22 | Blueprint Medicines BPMC Q2 2019 Earnings Call Transcript

2019-08-01 09:15:01 | Blueprint Medicines BPMC Reports Q2 Loss, Tops Revenue Estimates

2019-08-01 07:00:00 | Blueprint Medicines Reports Second Quarter 2019 Financial Results

2019-07-25 08:00:00 | Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019

2019-07-23 14:47:04 | 5 Biotech Stocks to Buy for a Strong Growth Prognosis

2019-07-18 16:01:00 | Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFR? D842V Mutant GIST and Fourth-Line GIST

2019-07-16 07:27:00 | 3 Soaring Biotech Stocks With More Fuel in the Tank

2019-07-10 09:25:00 | Here's Why Blueprint Medicines Stock Rose 75% in the First Half of 2019

2019-07-09 09:57:36 | Has Blueprint Medicines Corporation NASDAQ:BPMC Got Enough Cash?

2019-06-29 08:09:00 | 2 Stocks That Could Be the Next Biotech Buyouts

2019-06-20 09:41:01 | The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure

2019-06-19 11:20:03 | Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

2019-06-18 09:51:14 | Cancer Therapy Stocks Soar After Pfizer Deal

2019-06-18 07:31:03 | The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

2019-06-17 13:30:00 | Shares of cancer-therapy companies skyrocket after Pfizer acquisition news

2019-06-15 06:00:00 | Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress

2019-06-14 08:45:00 | Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

2019-06-10 09:39:55 | Hedge Funds Have Never Been This Bullish On Blueprint Medicines Corporation BPMC

2019-06-08 09:30:01 | Blueprint Medicines BPMC Up 7.3% Since Last Earnings Report: Can It Continue?

2019-06-06 09:17:39 | Life sciences VC firm Third Rock raises $770M in its largest round ever

2019-06-05 11:44:03 | Blueprint Medicines to File NDA for Avapritinib With FDA

2019-06-04 08:03:46 | See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

2019-06-03 16:24:31 | Who Are The Winners And Losers From The Year's Biggest Cancer Meeting?

2019-06-03 10:26:02 | Blueprint Medicines' NDA for Avapritinib on Track for GIST

2019-06-03 09:00:00 | Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019

2019-06-01 09:00:00 | Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib

2019-05-29 16:00:00 | Blueprint Medicines to Present at Upcoming Investor Conferences in June

2019-05-23 19:26:00 | 2 Top Stocks to Watch at ASCO 2019

2019-05-16 09:00:00 | Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations

2019-05-15 10:16:00 | 3 Stocks With Big News Coming at ASCO 2019

2019-05-14 11:12:30 | How Much is Blueprint Medicines Corporation's NASDAQ:BPMC CEO Getting Paid?

2019-05-13 08:44:12 | Blueprint Medicines BPMC Q1 Earnings & Sales Lag Estimates

2019-05-10 08:35:30 | Edited Transcript of BPMC earnings conference call or presentation 9-May-19 12:30pm GMT

2019-05-10 08:24:03 | Blueprint Medicines BPMC Q1 2019 Earnings Call Transcript

2019-05-09 08:35:12 | Blueprint Medicines BPMC Reports Q1 Loss, Misses Revenue Estimates

2019-05-09 07:23:27 | Blueprint Medicines: 1Q Earnings Snapshot